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1. Introduction 
Currently, corticosteroids are the most widely used class of anti-inflammatory drugs. The 
introduction of topical hydrocortisone in the early 1950s provided great advantages over 
previously available therapies and initiated a new era for dermatological therapy. Their 
clinical effectiveness in the treatment of dermatological disorders is related to their 
vasoconstrictive, anti-inflammatory, immunosuppressive and anti-proliferative effects. 
Despite their benefit in the therapy of inflammatory diseases, topical corticosteroids (TC) are 
associated number of side effects that limit their use. Most TC are absorbed in quantities that 
can produce both systemic and topical side effects [1-2]. Table 1 shows the currently used 
TC in various dermatological disorders according to the British classification system [3]. In 
general, mild and moderate TC are used for long-term treatments while the potent and very 
potent products especially preferred for shorter regimes. 
Over the years, research has focused on strategies to optimize the potency of steroids while 
minimizing adverse effects due to drug absorption across the skin. In other words, research 
focus no longer been on the synthesis of more potent derivatives but on safer one. Several 
attempts have been made to increase the safety of TC treatment, including new application 
schedules, special vehicles and new synthesized agents [4]. However, “ideal” TC have not 
yet been synthesized. They should be able to permeate the stratum corneum (SC) and reach 
adequate concentrations in the epidermis without reaching high systemic concentrations.   
One of the approaches to reduce the adverse effects of TC is to enhance their permeability so 
as to reduce the topically applied dose [5]. Several approaches have been attempted, such as 
iontophoresis, electroporation or the application of eutectic mixtures [6,7]. However, the use 
of chemical penetration enhancers is the most widely used approach to increase skin 
delivery [8]. 
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POTENCY DOSE % (w/w) TC 
Mild 
 Hydrocortisone 
1 Hydrocortisone acetate 
0.25 Methylprednisolone 
0.05 
Alclometasone 
dipropionate 
0.01-0.1 Dexamethasone 
0.0025 Fluocinolone acetonide 
0.75 Fluocortyn butyl ester 
0.5 Prednisolone 
Moderate 
0.05 Clobetasone butyrate 
0.02 Triamcinolone acetonide 
0.005 Fluocinolone acetonide 
Potent 
0.05 
Betamethasone 
dipropionate 
0.1 Betamethasone valerate 
0.025 Fluocinolone acetonide 
0.1 Hydrocortisone butyrate 
0.05 
Halometasone 
monohydrate 
0.1 Diflucortolone valerate 
Very potent 
0.1 Halcinonide 
0.05 Clobetasol propionate 
Table 1. The currently used TC in various dermatological disorders [3] 
TC are formulated in a variety of conventional vehicles, including ointments, creams, lotions 
and gels. In addition to conventional formulations several innovative systems such as 
nanoparticles, liposomes, microemulsions, foams and patches have been evaluated for 
different dermatological conditions. Colloidal drug carrier systems, such as liposomes and 
nanoparticles, could target TC to the viable epidermis, where the inflammatory reactions 
take place. In particular, liposomal preparations showed a strong affinity for the SC. Patents 
filed on topical nanoparticulate formulations also claimed the importance of colloidal drug 
carrier systems for this type of applications [9-12]. 
This chapter will review major innovations and advances in TC formulations based on the 
published articles and patent applications. The main factors influencing the effectiveness 
and bioavailability of TC will be also briefly discussed before emphasizing formulation 
alternatives. 
2. Skin structure 
The skin, in Latin called cutis, is considered the largest organ of the body, accounting more 
than 10% of the body mass and having an average surface of approximately 2 m2. The 
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thickness of the skin is highly variable (average thickness of 1.5 mm), depending of several 
factors as the anatomic location, age and sex. The functions of the skin have been classified 
as protective, homeostatic, or sensorial. To maintain its characteristics, this organ is in a 
continual renewing process [13].  
Anatomically, the skin consists on 3 basic layers: epidermis, dermis and subcutaneous 
tissues. Depending on the region considered, the epidermis is made of 4-5 sublayers that, 
from bottom to top, are: stratum basale, stratum spinosum, stratum granulosum, stratum 
lucidum (present only in palm and soles) and SC or horny layer. In addition to these 
structures, there are also several associated appendages: hair follicles, sweat glands, 
apocrine glands, and nails [14]. 
The most important skin function is permeability barrier function. The outermost layer of 
the epidermis, the SC, with its peculiar structure, plays an important role in permeability 
barrier function [15]. Due to its barrier properties, the skin membrane is equally capable at 
limiting the molecular transport from and into the body. Overcoming this barrier function 
will be the purpose of skin drug delivery. 
3. Clinical limitations and side effects of TC 
TC are successfully used in the treatment of several common cutaneous diseases but their 
major limitation is still their side effect potential. The most common side-effects occur 
locally in the areas of skin treated with the steroid. Probably the most well known is 
thinning of the skin (atrophy), which sometimes results in permanent stretch marks (striae). 
Fine blood vessels may swell and become prominent under the skin surface (telangiectasia), 
again a permanent change. In addition, there may be a temporary loss of pigment in the 
areas of skin treated; this may be more noticeable in dark-skinned people. Sometimes the 
skin may become allergic to the steroid, making the eczema appear to get worse. The skin 
may also bruise more easily and become more susceptible to infection.  
The occurrence and severity of the side effects are depend on the duration of use, dosage, 
dosing regime and spesific drug used, along with individual patient variability. However, 
the highest risk factor seems to be prolonged use [16-18]. The concentration of corticosteroid 
in systemic circulation and risk of sytemic side effects are increased by prolonged therapy 
with TC. Systemic side-effects of TC, such as pituitary–adrenal axis suppression, should be 
taken into account when treating children. Children have a higher ratio of total body surface 
area to body weight (about 2.5- to 3-fold that of adults) and adrenal suppression may cause 
growth retardation.  
The principle systemic side effects associated with TC are bodyweight gain, Cushing’s 
syndrome, electrolyte imbalance, hypertension, diabetes mellitus, pseudoprimary 
aldosteronisim, growth retardation, osteoporosis peptic ulser and gastritis. In addition, TC 
are mostly capable of causing local side effects. One particularly important local side effect 
is epidermal thinning or atrophy [19]. This effect is characterized with the reduction in cell 
size and number of cell layers in epidermis. Other local side effects related to TC treatment 
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are steroid acne, rosacea, perioral dermatitis, corticoid acne, allergic contact dermatitis, 
hypopigmentation, glaucoma, cataracts, worsening of cutaneous infections and 
hypertrichosis [2]. Table 2 represents the possible local and systemic side effects of TC which 
are organized in subsections for tissue-organ level. 
 
TISSUE - ORGAN SIDE EFFECTS
Cardiovascular system Hypertension 
Endocrin system Adrenal insufficiency, Cushing’s syndrome, diabetes 
mellitus, bodyweight gain, pseudoprimary aldosteronism 
Eye Glaucoma, cataract
Immune system Increased risk of infection, re-activation of latent viruses 
Gastrointestinal Peptic ulser, gastritis 
Central nervous system Behavioural changes, loss of memory/cognition 
Skeleton and muscle Growth retardation, osteoporosis
Skin Atrophy, striae, allergic contact dermatitis, delayed 
wound healing, steroid acne, perioral dermatitis, rosacea,  
erythema, teleangiectasia, hypertrichosis, 
hypopigmentation 
Table 2. The possible local and systemic side effects of TC 
4. Classification of TC 
TC are classified in two different ways by American and British National Formulary 
classification systems [20-21]. The American classification system includes seven potency 
groups while the British National Formulary contains four groups. In the former system, the 
potency of a product is defined by the corticosteroid, its concentration and the nature of the 
vehicle. On the other hand, The British classification system is irrespective of the topical 
vehicle used. According to the American classification sytem, it is important to note that the 
greater in potency for TC result in the greater therapeutic efficacy and side effects. 
Therefore, low-potency formulations should be used for long term treatments by physicians 
while the more potent products should be chosen for short periods and sites such as palms 
and soles, where low potency TC are ineffective [1,2]. 
5. Formulations of TC 
It is well known that, besides the active molecule, the potency of each topical formulation 
can be influenced by vehicle characteristics. Vehicles should allow adequate release of the 
active compound, spread easily and be aesthetically pleasant [21]. Some important rules 
should be considered when choosing a vehicle; the solubility, release rate and stability of the 
therapeutic agent in the vehicle, the ability of the vehicle to hydrate the SC, the physical and 
chemical interactions of the vehicle with the skin and active molecule and also the phase, 
localization and extent of disease [22].  
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TC are formulated in a variety of conventional vehicles, including ointments, creams, lotions 
and gels. As mentioned previously, the character of the vehicle system defines the potency 
of topical preparations and its selection is crucial for product performance. 
Ointments are semi-solid preparations intended for application to skin or mucous 
membranes. There are four types of ointment bases; hydrocarbon bases, absorption bases, 
emulsion bases and water-soluble bases. The potential of the absorption is affected by choice 
of the bases. Hence, appropriate selection of the base is important for the efficacy of the 
dermal therapy [23].  
Ointment formulations are generally more effective than creams containing the same drug 
and they are especially preferred for infiltrated, lichenified lesions. In a comparative study, 
the absorption of clobetasol propionate from ointment and cream formulations was 
evaluated and it was reported that a greater amount of clobetasol propionate was absorbed 
from the ointment [24]. Ointments including well-known and new synthesized TC were 
formulated and they were still first-option for treatment of dermatological diseases. 
However, the greasy nature and hardness of the removal from the skin due to their lack of 
water-washability is their disadvantages. 
Mobile dispersions intended for topical application are generally described as lotions and 
semi-solid systems as creams. Although, creams are usually emulsions of the oil-in-water 
type (aqueous creams) or water-in-oil type (oily creams), lotions are mostly oil-in-water 
emulsions [25]. Regarding to the phase of disease, lotions and creams are generally 
recommended in acute and subacute dermatoses. Good compliance is obtained by 
prescribing creams and lotions which are easily applied by patients rather than ointments in 
case of large extensional dermatoses. Sequeira et al. [26] filed a patent application which 
provided a corticosteroid lotion formulation exhibiting high vasoconstrictor and excellent 
anti-inflammatory activities in steroid responsive dermatoses. The addition of propylene 
glycol to a hydro-alcoholic lotion base exhibited and significantly higher vasoconstrictor 
activity than the corresponding lotion without propylene glycol. 
Gels are semi-solid systems with dispersions of small or large molecules in an aqueose 
vehicle with a gelling agent. The gel formulations are suitable for topical delivery of drugs 
for treatment of diseases due to lack of irritating components. Pharmaceutical gel 
formulations for topical drug delivery include drug and gelling agent [27]. Gels based on 
carbopol, cellulose derivatives and chitosan are commonly used in the pharmaceutical and 
cosmetic industries [28, 29].  
Recently, new hydrogel formulation intended for cosmetic use was introduced as a novel 
formulation of steroids for the treatment of atopic dermatitis. The formulation was prepared 
with carbopol-based polymer that contained 0.05% (w/w) of micronized desonide which is a 
well-known synthetic corticosteroid. This formulation was easily applied for atopic 
dermatitis patients aged 3 months. A wide variety of studies have been performed to 
validate the safety and efficacy of this product and these studies supported very favourable 
safety, tolerability and efficacy profile [30, 31]. 
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Senyigit et al. [32] investigated the effect of vehicles (chitosan and sodium-deoxycholate 
gel) on the skin accumulation and permeation of two topical corticosteroids: clobetasol 
propionate and mometasone furoate. Commercial cream formulations containing the 
same amount of drug were also used for comparison. It was reported that sodium-
deoxycholate gel formulation dramatically improved the amount of drug in the skin 
although chitosan gel produced the same skin accumulation as commercial creams for 
both active agents. In addition, all of these gel formulations did not induce the 
permeation.  
For conventional formulations it can be stated that the effectiveness of the active agent is 
directly related to the composition of the formulation. In general, the potency of the 
corticosteroids in the formulations could be listed in order such as; ointments> gels> 
creams> lotions. This generalization was supported with a patent filed by McCadden [33]. 
The brief summary about conventional TC formulations including pharmaceutical 
characteristics, clinical usage, benefits and disadvantages were given in Table 3. 
 
Formulation 
type 
Pharmaceutical 
characteristics 
Clinical 
usage 
Benefits Disadvantages 
Ointment Semi-solid 
preparations 
containing 
different types of 
ointment bases 
Infiltrated, 
lichenified 
lesions 
Occlusive 
property on the 
skin for inducing 
skin hydration at 
the skin-ointment 
interface 
Greasy nature 
and hardness 
of the removal 
from the skin 
due to their 
lack of water-
washability 
Cream Oil-in-water 
(aqueous creams) 
or water-in-oil 
(oily creams) type 
of emulsion 
Acute and 
subacute 
dermatoses 
Easy application 
and good patient 
compliance 
Difficulty of 
spreadability 
and soiling 
linen and 
clothing during 
treatment for 
oily creams 
Lotion Generally oil-in-
water emulsions 
Acute and 
subacute 
dermatoses 
Easy application 
and good patient 
compliance 
Not suitable for 
use on dry skin 
Gel Dispersions 
formulated with a 
gelling agent 
Suitable for 
all types of 
skin diseases 
Easy application, 
easy to attach to 
the skin, good 
patient 
compliance and 
lack of irritating 
components 
- 
Table 3. The summary about conventional TC formulations 
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The activity of a TC formulation can be enhanced by adding a chemical penetration 
enhancer which may result in an increase of drug delivery into skin. Chemical penetration 
enhancers have been reviewed by several researchers and the authors underline the 
difficulty to select rationally a penetration enhancer for a specific permeant [34-36]. Recent 
studies showed that terpenes appear to be promising penetration enhancers for 
pharmaceutical formulations with favourable properties such as low cutaneous irritancy 
and possess good toxicological profile [32, 37]. 
Recently, it has been a great interest in developing new drug carriers for TC that may 
contribute to reduction of side effects. Therefore, in addition to previously mentioned 
conventional formulations several innovative systems such as nanoparticles, liposomes, 
microemulsions, foams and patches have been developed for TC.  
Liposomes, microemulsions, solid lipid and polymeric nanoparticles have been proposed to 
increase percutaneous absorption of therapeutic agents while mitigating the damage to the 
skin barrier function [38,39]. Besides, the drug targeting to the skin or even to its 
substructures could be realized by micro- and nanoparticulate systems [40,41]. These drug 
carrier systems could target glucocorticoids to the viable epidermis, where the inflammatory 
reactions take place [9]. In particular, liposomal preparations showed strong affinity for the 
SC [42].  
The loading of therapeutic agents into nanoparticles and administration to the skin using a 
simple vehicle offer many advantages over other traditional topical formulations, including 
enhanced formulation aesthetics, protection of unstable active agents against degredation, 
targeting of active agents to the skin layers and prolonged active agent release [43]. As a 
consequence of their proposed advantages in dermal/transdermal formulations two most 
common types of particles have been produced: Lipid nanoparticles and polymeric 
nanoparticles. The uses of lipid and polymeric nanoparticles for pharmaceutical 
formulations applied to skin have been reviewed by several authors [40, 44-46]. Most of the 
data reported on TC was obtained using lipid nanoparticles of differing lipid compositions. 
The inclusion of prednicarbate into solid lipid nanoparticles (SLN) of various composition 
appeared to increase the penetration of the drug into human skin by 30% as compared to 
cream, permeation of reconstructed epidermis increased even 3-fold [47]. In a subsequent 
report SLN were shown to induce prednicarbate targeting in the epidermal layer in excised 
human skin and reconstructed epidermis [9]. Epidermal targeting was evidenced also for 
prednisolone, the diester prednicarbate and the monoester betamethasone 17-valerate 
included in solid lipid nanoparticles [48]. The authors hypothesized specific interactions of 
the drug-carrier complex and the skin surface, possible by the lipid nature and nanosize of 
the carrier. On the other hand, using the appropriate lipid combination, the skin retention of 
betamethasone 17 valerate was increased when SLN was used as a vehicle compared to a 
conventional formulations [49], both using intact skin as well as barrier impaired [50]. 
Clobetasol propionate was included in SLN as well [51]. SLN containing cream registered 
significant improvement in therapeutic response (1.9 fold inflammation, 1.2 fold itching) in 
terms of percent reduction in degree of inflammation and itching against marketed cream.  
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de Vringer disclosed a stable aqueous suspension of SLNs, comprising at least one lipid and 
preferably also at least one emulsifier for topical application to the body. According to this 
invention steroidal anti-inflammatory compound such as hydrocortisone, hydrocortisone-
17α-butyrate, budesonide or TA, anti-proliferatives, anti-psoriatics, anti-eczema agents and 
dithranol could be succesfully incorporated into the suspension of SLNs. It was stated that a 
combination of two or more topically effective medicaments could also be used [52]. 
Senyigit et al. [53] prepared lecithin/chitosan nanoparticles containing clobetasol propionate 
and found a preferential retention in the epidermis while no permeation across the skin was 
observed. In vivo studies including transepidermal water loss measurements, anti-
inflammatory effect and histological evaluation of the formulations on wistar albino rats 
were also performed and the results were promising (Data not published). 
Liposomes are lipid vesicles prepared with phospholipids which have been shown to 
facilitate transport of drugs into and across skin [54]. Recently, many reports have been 
published on percutaneous enhancing property of liposomes for both hydrophilic and 
lipophilic compounds [55]. Liposomes do not only enhance the drug penetration into the 
skin by showing slow release, but also decrease the clearence of drug by minimizing its 
absorption into the systemic circulation [56]. Hence, the liposomes can improve the 
therapeutic effectiveness of TC while reducing systemic side effects. However, many 
stability problems are reported for liposomes.  
Mezei et al. [57, 58] applied triamcinolone acetonide (TA) in liposomes and compared it 
with TA in Dermabase®. In this study, four- to five fold higher TA concentrations in the 
epidermis and dermis, with lower systemic drug levels were observed when the drug was 
delivered from liposomal lotion in comparison with conventional formulations of the same 
drug concentration.  
Lasch and Wohlrab [59, 60] studied the skin distribution of cortisol and hydrocortison after 
application in a cream and liposomes. As a result, improved concentration-time profile was 
observed in skin layers by liposomes for both drugs.  
Korting et al. [61] compared the efficacy of betamethasone dipropionate encapsulated in 
liposomes and cream. The liposomes were prepared with egg lecithine and incorporated in 
a polyacrylate gel. The in vivo studies were carried out in patients with atopic eczema and 
psoriasis vulgaris. It was concluded that, betamethasone encapsulated in liposomes 
improved the antiinflammatory action, but not the antiproliferative effect.  
Fresta et al. [62] prepared skin-lipid liposome formulations of different corticosteroids 
(hydrocortisone, betamethasone valerate and TA). They indicated that skin lipid liposomes 
showed a 6 and 1.3 fold higher blanching effect than control formulations of ointment and 
the phospholipid-based liposomes, respectively. Skin-lipid liposomes also produced a 
reduction in drug levels in the blood and urine. Consequently, this liposome formulation 
was proposed for improving the pharmacological effectiveness and reducing the systemic 
absorption of TC. 
In order to overcome the stability problem of liposomes, new attempts have been maden 
and new drug carrier systems have been developed by adding some functional chemicals 
into the liposome structure. These systems are niosomes, transfersomes and ethosomes. 
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Niosomes, non-ionic surfactant vesicules, are widely studied as an alternative to liposomes 
for topical and transdermal drug delivery. Niosomes alleviate the disadvantages associated 
with liposomes, such as chemical instability, variable purity of phospholipids and high cost. 
In addition, they have the potential for controlled and targeted drug delivery to the skin [63-
65]. Deformable liposomes (Transfersomes®) are the first generation of elastic vesicles 
introduced by Cevc [66]. They consist of phospholipids and an edge activator. An edge 
activator is often a single chain surfactant that destabilizes lipid bilayers of the vesicles and 
increases deformability of the bilayers [67-68].  
Cevc et al. [69] investigated the regio-specificity potential of transfersomes which included 
different corticosteroids (hydrocortisone, dexamethasone and TA). They demonstrated that 
transfersomes ameliorate the targetability of all tested corticosteroids into the viable skin. 
They also suggested that the introduction of transfersomal corticosteroids creates new 
opportunities for the well controlled topical medication.  
In another study performed by Fesq et al. [70], the efficacy of transfersomes was compared 
with commercially available cream and ointment formulations of TA in humans. According 
to the results of this study, 10-fold lower dose of TA in transfersome was found 
bioequivalent to conventional formulations as measured by erythema suppression. 
Ultrasonic measurements also revealed significantly reduced atrophogenic potential of 
transfersomes in comparison to commercial formulations.  
Ethosome is another novel lipid carrier showing enhanced skin delivery and recently 
developed by Touitou. The ethosomal system is composed of phospholipid, ethanol and 
water. The use of high ethanol content was decribed for ethosomes although liposomal 
formulations containing up to 10% ethanol [71, 72]. 
Microemulsions are thermodynamically stable, transparent, isotropic, low-viscosity 
colloidal dispersions consisting of microdomains of oil and/or water stabilized by an 
interfacial film of alternating surfactant and cosurfactant molecules [73]. Microemulsions are 
effective formulations for the dermal and transdermal delivery of particularly lipophilic 
compounds like TC because of their solubilizing properties and also their components may 
act as penetration enhancers [74, 75].  
Wiedersberg et al. [76] studied the dermato-pharmacokinetic properties of betamethasone 
valerate from two different formulations either in the reference vehicle consisting of 
medium chain triglycerides or in the microemulsion. The results showed that 
microemulsion significantly increased the extent of drug delivery into the SC. 
In another study, the penetration behaviour of hydrocortisone from the microemulsion 
system and a commercialy available cream formulation containing the same amount of 
hydrocortisone (0.5%) was investigated. Ex vivo penetration studies on human breast skin 
were carried out and the drug contents in the different skin layers were measured. With 
regard to the cream, the results showed that, a higher percentage of hydrocortisone was 
found in the epidermis and dermis. This result pointed out the skin targeting effect achieved 
by microemulsion formulation [77, 78]. 
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Formulation 
type 
Pharmaceutical 
characteristics 
Benefits Disadvantages 
Nanoparticles Solid lipid 
nanoparticles include 
solid or the mixture of 
solid and fluid lipids 
 
Polymeric 
nanoparticles contain 
non-biodegradable and 
biodegradable 
polymers 
Enhanced formulation 
aesthetics, protection of 
unstable active agents 
against degredation, 
targeting of active 
agents to the skin layers 
and prolonged active 
agent release 
Mechanism of 
interaction 
between 
nanoparticles - 
skin structures 
and in vivo 
toxicity issues 
are need to be 
clarified 
Liposomes Lipid vesicles prepared 
with phospholipids 
Percutaneous absorption 
enhancing property, 
slow release and  
decrease the clearence of 
drug by minimizing its 
absorption into the 
systemic circulation 
Stability 
problems 
Niosomes Non-ionic surfactant 
vesicules 
Alleviate the 
disadvantages 
associated with 
liposomes, such as 
chemical instability, 
variable purity of 
phospholipids and high 
cost. 
 
Controlled and targeted 
drug delivery to the 
skin. 
Less effective 
drug delivery in 
comparison to 
liposomes 
Transfersomes Consist of 
phospholipids and an 
edge activator 
Improved therapeutic 
risk-benefit ratio,due to 
better targeting and 
longer drug presence in 
the skin 
- 
Ethosomes Composed of 
phospholipid, ethanol 
and water. 
Improved 
dermal/transdermal 
delivery of lipophilic 
or hydrophilic 
molecules 
The mechanism 
of action is not 
clear 
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Formulation 
type 
Pharmaceutical 
characteristics 
Benefits Disadvantages 
Microemulsions Thermodynamically 
stable, transparent, 
isotropic, low-viscosity 
colloidal dispersions 
consisting of 
microdomains of oil 
and/or water stabilized 
by an interfacial film of 
alternating surfactant 
and cosurfactant 
molecules 
Ease of manufacturing 
and high loading 
capacity. 
 
Effective formulations 
for the dermal and 
transdermal delivery of 
particularly lipophilic 
compounds. 
- 
Patches Drug delivery systems 
intended for skin 
application 
Provides the 
administration of 
effective and known 
drug amount to the skin 
and the occlusive effect 
Skin irritation 
Foams Incorporate active 
agents, solvents, co-
solvents, surfactants 
and propellants in a 
sealed canister under 
pressure 
More convenient topical 
drug delivery with easy 
application and 
spreadability 
characteristics in 
comparision to other 
topical dosage forms 
- 
Table 4. The summary about innovative TC formulations 
Patches are other innovative drug delivery systems intended for skin application in view of 
achieving local or systemic effect. The patch provides the administration of effective and 
known drug amount to the skin [79]. 
The occlusive effect of Actiderm® (hydrocolloid dermatological patch) has been studied on 
the percutaneous penetration of several drugs including corticosteroids. It was found to be 
effective in controlling and sustaining the localized delivery of the steroid into the skin and 
enhancing the healing of dermatological disorders [80, 81].  
Ladenheim et al. [82] investigated the effect of occlusion on in vitro TA penetration using 
hydrocolloid containing patches by measuring transepidermal water loss. They found that 
the diffusion rate of TA was increased 3-4 fold when applied occluded patch in comparison 
with unoccluded. Same research group was also evaluated the occlusive properties of a 
range of hydrocolloid patches containing TA on the drug penetration in vivo using visual 
assessment and the graded multiple-measuremet procedure. They concluded that these 
patch formulations showed great potential for localized prolonged delivery of drugs to the 
skin, which would be desirable for the topical use of other corticosteroids [83]. 
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More recently, novel foam formulations of TC have been developed and proposed as 
alternative therapy to conventional formulations. They offer more convenient topical drug 
delivery with easy application and spreadability characteristics in comparision to other 
topical dosage forms [84, 85]. 
A novel foam formulation with enhanced BMV bioavailability has been shown to be 
superior in efficacy when compared with a lotion in the treatment of disease, without an 
concomitant increase in toxicity [86]. Another study has been performed comparing the 
ability of a foam formulation to release the active ingredient (betamethasone benzoate) with 
ointment, gel, and cream formulations. It was found that the release of betamethasone 
benzoate from the foam formulation better than the release from the cream [87]. 
The thermolabile and low-residue foam formulations of corticosteroids (betamethasone 
valerate and clobetasol propionate) are available in USA market. These foam formulations 
are associated with better patient compliance and improvements in quality of life [88, 89]. 
Table 4 summarizes the new drug carrier formulations of TC. 
6. Conclusion 
Current therapy of dermatological disorders with conventional dosage forms including 
TC is insufficient due to the low absorption rate and the risk of side effects. Therefore, it is 
necessary to synthesize the new topical corticosteroid molecules with adequate anti-
inflammatory activity and minimal side effects. Fluticasone propionate, mometasone 
furoate and prednicarbate are very promising molecules showed lower side effects and 
better tolerability as a member of new generation TC. Also, improved dermal absorption 
of established TC may be obtained by new designed vehicle system as an alternative to 
conventional formulation. Recently, lipid and polymeric based carriers such as liposomes, 
niosomes, transfersomes, ethosomes, microemulsions and nanoparticles have been 
studied intensively and the potential of these carrier systems have also been described. 
Another alternative approach for TC treatment is a combined therapy which is more 
effective than in case of drug alone. The combined use of TC and synthetic vitamin D 
analogues such as calcipotriol would be promising for the treatment of inflammatory skin 
diseases. I 
In conclusion, due to the difficulty of synthesizing new steroid molecules, developing the 
novel alternative drug carrier systems which improve the risk-benefit ratio of TC would 
be more beneficial in topical corticosteroid treatment. Besides, more in vivo study is 
required to validate the ability of new formulations in enhancing topical delivery of 
corticosteroids. 
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